Diabetic cardiomyopathy
1Department of Cardiology, Faculty of Medicine, Kocaeli University, Kocaeli-Turkey
2Department of Cardiology University of Kocaeli School of Medicine, Kocaeli, Turkey
3Department of Cardiology, Medical Faculty of Kocaeli University, Kocaeli, Turkey
Anatol J Cardiol 2011; 11(8): 732-737 PubMed ID: 22137942 DOI: 10.5152/akd.2011.196
Full Text PDF

Abstract

Diabetic individuals are at significantly greater risk of developing heart failure (HF) independent from other risk factors such as coronary artery disease (CAD) and hypertension. Diabetic cardiomyopathy (DCP) is defined as ventricular dysfunction in the absence of hypertension, coronary artery and valvular heart disease, which increases the risk of HF. Due to better understanding of its pathophysiology and clinical importance, DCP is more frequently recognized in daily practice. The most important mechanisms of DCP are hyperglycemia, insulin resistance/hyperinsulinemia, abnormal fatty acid metabolism, increased apoptosis, cardiac autonomic neuropathy and local renin-angiotensin-aldosterone system (RAAS) overactivation. Echocardiography is the most frequently used diagnostic method for the detection of this pathology. Currently, although there is no specific treatment for DCP, strict glycemic and concomitant risk factor controls seems to be the most important target strategy for prevention of the progression and treatment of DCP. In this article, we aim to provide an extensive review on the pathophysiology, diagnosis, management of DCP.